SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Middle East shipping and energy-infrastructure attack concerns are driving crude higher and drawing attention to USO, which tracks WTI futures. Traders are split between bullish supply-disruption fears and bearish calls for a pullback if tensions ease, with some warning the rally is stretched.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves selloff is centered on concerns that its debt-heavy AI infrastructure buildout could become harder to finance if borrowing costs stay high or AI demand slows, amplified by bearish HSBC commentary and pressure across neocloud stocks. Traders are split between warnings of further downside and default risk, and bullish arguments that the companys backlog and AI demand support a rebound.

USA Rare Earth, Inc. is a domestic supplier of rare earth magnets and heavy rare earth elements. It develops a vertically integrated domestic supply chain for rare earth element magnet production, with a facility in Stillwater and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

A steep selloff in USAR and the broader rare-earth sector is driving discussion, with traders pointing to dilution concerns, heavy spending before large-scale production and weak sentiment around management. Some blame short selling or broader market pressure, while bulls argue the companys government backing and domestic magnet ambitions support its long-term case and see the decline as oversold.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO decline is drawing attention, with traders focused on successive share-lockup expirations and reported insider selling as potential sources of supply, alongside a price-target cut and weakness in AI stocks. Bears see continued pressure from valuation and execution concerns, while bulls argue the selloff is overdone and point to the companys AI-chip technology and long-term potential.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

UBSs downgrade of NuScale to Sell, citing long commercialization timelines and a lack of firm customer commitments, is driving the selloff. Traders debate whether it signals deeper execution risks, including delays around the TVA opportunity, or overstates the concerns amid weakness across nuclear stocks; some view the decline as a buying opportunity.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicors Q3 results are driving discussion, with traders emphasizing strong revenue growth and improved margins while debating the GAAP EPS shortfall and the lack of forward guidance. Some view the AI power-delivery and licensing growth as encouraging, while others are cautious about valuation and whether the earnings news is enough to support the stock.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs quarterly earnings beat and new multiyear buyback are drawing attention, but shares are falling as traders question why the stock dropped despite the results. The debate centers on the unchanged profit-outlook midpoint and weaker vehicle sales versus the buyback and stronger cash-flow outlook.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

A sharp pullback across AI and neocloud stocks has focused attention on fears that infrastructure spending may not deliver returns and that tighter financing could pressure providers, with CoreWeaves debt concerns often cited as a sector risk. Traders are divided between buying Nebiuss rebound as an oversold dip and expecting more downside until funding and market conditions improve.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStops warrant-expiration notice is driving discussion, as traders debate whether the approaching deadline and possible dilution are weighing on shares or whether unexercised warrants would remove dilution risk. Sentiment is split between frustration with Ryan Cohen and speculation about an extension or other corporate action; those hopes remain unconfirmed.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led rebound in the Nasdaq-100 after a sharp AI-stock selloff, ahead of major technology earnings, has put QQQ in focus. Traders are split over whether the bounce can hold or is a temporary relief rally, citing concerns about AI financing, narrow market breadth and rising oil-related inflation risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AT&T Teams Up With LifeMD for Virtual Health Care: Can it Aid Shares?

T expands customer benefits with complimentary LifeMD memberships, offering virtual care, prescriptions and pharmacy services.

AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMD

AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMD AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMDPR NewswireDALLAS, Sept. 15, 2026 DALLAS, Sept. 15, 2026 /PRNewswire/ -- Through an exclusive...

LifeMD, Inc. (LFMD) Reports Q2 Loss, Lags Revenue Estimates

LifeMD (LFMD) delivered earnings and revenue surprises of +20.00% and -3.70%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

LifeMD's Series A Preferred Stock Crosses Above 9.5% Yield Territory

In trading on Monday, shares of LifeMD Inc's 8.875% Series A Cumulative Perpetual Preferred Stock (Symbol: LFMDP) were yielding above the 9.5% mark based on its quarterly dividend (annualized to $2.2188), with shares changing hands as low as $22.91 on the day. As of last clos...

CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last?

CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Hims & Hers Expands Integrated Health Access via Platform Expansion

HIMS expands its integrated telehealth ecosystem with a new weight-loss membership and a planned Eucalyptus acquisition to broaden virtual care.

Is CAH Becoming the Backbone of US Healthcare Infrastructure?

Cardinal Health is expanding beyond drug distribution into specialty care, logistics and nuclear medicine, deepening its role in US healthcare infrastructure.

Bloomberg Businessweek Daily 5/18/2026

Today, Matt Schettenhelm, Bloomberg Intelligence Senior Litigation Analyst, breaks down a California's jury's rejection of Elon Musk's claim that Sam Altman betrayed OpenAI's original mission when it...

LifeMD (NASDAQ:LFMD) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS

LifeMD (NASDAQ:LFMD - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.06). LifeMD had a negative return on equity of 83.93% and a net margin of 6.58%.The business had...

LifeMD, Inc. (LFMD) Reports Q1 Loss, Tops Revenue Estimates

LifeMD (LFMD) delivered earnings and revenue surprises of -42.86% and +3.97%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

LifeMD, Inc. is a telehealth company, which engages in offering a portfolio of direct-to-patient products and services. The firm combines virtual medical treatment with prescription medications and over-the-counter products. It operates through the Telehealth and WorkSimpli segments. The company was founded by Justin Schreiber on May 24, 1994 and is headquartered in New York, NY.

LifeMD Inc

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Hims shares logged their best session in a month and added after-hours gains.</li><li>Novo expanded oral Wegovy access, while Citi kept a ‘Sell’ rating on Hims.</li><li>Hims continues to broaden its platform through international expansion and new services.</li></ul>Hims &amp; Hers Health Inc. shares posted their strongest session in a month on Monday and added another 0.7% in after-hours trading, with both trading days so far this year ending higher.The move came despite a cautious note from Citi, which said Novo Nordisk’s latest Wegovy announcement could pressure Hims’ GLP-1 business in 2026. Citi kept a 'Sell' rating on the stock with a $30 price target.<h2 class="st-heading-2">Novo’s Oral Wegovy Move Leaves HIMS On The Sidelines</h2>Novo Nordisk said on Monday that its oral Wegovy pill is now broadly available in the U.S., with pricing starting at $149 a month for specific doses and higher prices for larger doses later in 2026. Novo also said commercially insured patients could access the pill for as low as $25 per month.Citi said Hims was again left off Novo’s list of partners, which includes CVS Health, Costco, LifeMD and GoodRx. The firm said this likely reflects disagreements between Novo and Hims around Hims’ compounded semaglutide strategy, and added that the broader rollout of Wegovy pills could put pressure on Hims’ GLP-1 business this year.<h2 class="st-heading-2">Broader Growth Drivers Remain in Focus</h2>Hims &amp; Hers Health has spent recent months expanding its platform beyond weight loss through geographic expansion, new product launches and acquisitions. In December, the company announced the expansion of its Weight Loss Program to the UK, including the official launch of the Hers platform for eligible women, offering access to weight-management care following assessments by GMC-registered doctors. The UK offering includes branded GLP-1 options and oral non-prescription treatments.Hims has also entered Canada following the completion of its acquisition of Livewell, a Canadian digital health platform. Additionally, the company said it will acquire YourBio Health, which develops capillary whole blood sampling technology, including the TAP device that uses bladeless microneedles.&nbsp;Separately, Hims launched its Labs in-depth testing experience, which provides customers with blood-based biomarker testing and doctor-developed action plans across areas such as heart health, metabolism, hormones and inflammation. The company said it plans to expand the Labs offering over time to include additional biomarker tests, at-home testing devices and advanced diagnostics.In December, Barclays initiated coverage of Hims with an ‘Overweight’ rating and a $48 price target, noting that expectations for the business had become more reasonable and pointing to the addition of other growth drivers for FY26.<h2 class="st-heading-2">Investors Look Beyond Near-Term GLP-1 Pressure</h2>Competition in the GLP-1 weight-loss space continues to broaden. Novo Nordisk and Eli Lilly dominate the market with Wegovy and Zepbound, respectively, and Lilly’s injectable Zepbound has been shown in a head-to-head study to deliver greater average weight loss than Wegovy. Novo has since launched the first FDA-approved oral GLP-1 for weight loss, while Lilly is advancing its own oral candidate, orforglipron, which is under regulatory review. Both companies have also cut cash-pay prices for lower doses as access expands beyond insurance-covered channels.Beyond Novo and Lilly, other drugmakers are developing next-generation obesity treatments, including Lilly’s retatrutide and Novo’s CagriSema, while additional companies such as Pfizer and Structure Therapeutics are working on oral weight-loss drugs.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_55bef6044e.webp" alt="hims ss.png" width="972" height="144"><figcaption>HIMS sentiment and message volume as of January 5| Source: Stocktwits</figcaption></figure>One user said, “Injections vs pills for weight loss will be a big deal. Who wouldnt rather take a pill. HIMS needs to get Novo deal or somehow get access to sell the pill, otherwise their weight loss related revenue will tank”<stembedurl>https://stocktwits.com/Matril/message/640906333</stembedurl>Another user said that with GLP-1 pills now available through large retailers such as Costco, the downside risks are already reflected in the stock price, and added that future catalysts could include share buybacks and increased trading activity.<stembedurl>https://stocktwits.com/ros_/message/640880655</stembedurl><a href="https://stocktwits.com/symbol/HIMS">Hims’ stock</a> has risen 30% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

Costco Wholesale Corp

CVS Health Corp

GoodRx Holdings Inc

Structure Therapeutics Inc - ADR

Hims & Hers Health Inc

Lilly(Eli) & Co

Novo Nordisk A/S

Pfizer Inc

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$2.25
Prev Close	$2.34
Open	$2.35
Dividend Yield	0.00%
50-Day Moving Average	$3.03
Beta	1.67
Avg. Volume	860,685.08
PE Ratio	-4.36

52-Week High	$6.44
52-Week Low	$2.23
Market Capitalization	$112.79M
EPS (Annual)	-$0.2263
Price to Book	13.51
Revenue Per Employee	$498,856.55

Feed

News

Sentiment

Earnings

Fundamentals

Info

LFMD Fundamentals